Loading stock data...

Marksans Pharma Limited

NSE: MARKSANS BSE: MARKSANS

NSE
172.93 -1.27 (-0.73%)

Prev Close

174.2

Open Price

175.5

Volume

665,833

Today Low / High

172.51 / 176.37

52 WK Low / High

165.52 / 358.7

Range

164 - 182

BSE
173.00 -1.25 (-0.72%)

Prev Close

174.25

Open Price

174.45

Volume

106,292

Today Low / High

172.5 / 175.75

52 WK Low / High

165.45 / 358.5

Range

164 - 182

The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 172.93 (target range: 164 - 182), reflecting a change of -1.27 (-0.72905%). On the BSE, it is listed at 173 (target range: 164 - 182), showing a change of -1.25 (-0.71736%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.

12 Sep 175.50 -1.46%
11 Sep 177.45 -1.83%
10 Sep 173.61 1.90%
09 Sep 170.85 0.67%
08 Sep 170.26 -0.45%
05 Sep 171.51 -1.52%
04 Sep 176.95 -3.03%
03 Sep 172.00 0.59%
02 Sep 169.90 0.62%
01 Sep 169.40 -1.20%
29 Aug 170.00 -0.82%
28 Aug 173.27 -2.19%
26 Aug 178.37 -2.86%
25 Aug 181.00 -1.75%
22 Aug 181.60 -0.90%
21 Aug 182.99 -1.02%
20 Aug 185.50 -2.16%
19 Aug 185.30 -0.55%
18 Aug 180.00 2.36%

Marksans Pharma Limited Graph

Marksans Pharma Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges

If you are looking for the target price for Marksans Pharma Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 172.93, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.

Scenario Price Target Range
Bullish Scenario 173.00 174.73 157.26 - 192.20
176.46 141.17 - 211.75
178.19 124.73 - 231.65
Bearish Scenario 173.00 171.27 154.14 - 188.40
169.54 135.63 - 203.45
167.81 117.47 - 218.15

Overview of Marksans Pharma Limited

ISIN

INE750C01026

Industry

Drug Manufacturers - General

Vol.Avg

1,488,422

Market Cap

78,365,650,520

Last Dividend

1.4

Official Website

Visit Website

IPO Date

2002-07-19

DCF Diff

66.81

DCF

106

Financial Ratios Every Investor Needs

Stock Dividend of MARKSANS

Date Label Adj Dividend Dividend Record Date Payment Date Declaration Date
2025-08-01 August 01, 25 0.8 0.8 2025-08-01 2025-08-21
2024-09-17 September 17, 24 0.6 0.6 2024-09-17 2024-10-05
2023-06-07 June 07, 23 0.5 0.5 2023-06-07 2023-09-27
2022-08-19 August 19, 22 0.25 0.25 2022-08-22 2022-09-28
2021-09-15 September 15, 21 0.25 0.25 2021-09-16 2021-10-23

Stock Rating Details for MARKSANS

Metric Value Recommendation
Overall Rating C- Strong Sell
DCF Score 4 Buy
ROE Score 1 Strong Sell
ROA Score 1 Strong Sell
Debt-to-Equity (DE) Score 1 Strong Sell
Price-to-Earnings (PE) Score 1 Strong Sell
Price-to-Book (PB) Score 1 Strong Sell

Annual Financial Income Report

Date Revenue Co.Rev GP GPR R&D Expenses G&A Expenses Operating Income Net Income EPS EBITDA NIR
2025-03-31 2,622.85 Cr 1,143.74 Cr 1,479.10 Cr 0.5639 0.00 Cr 24.57 Cr 1,128.80 Cr 380.58 Cr 8.40 528.64 Cr 0.1451
2024-03-31 2,177.41 Cr 1,094.24 Cr 1,083.17 Cr 0.4975 19.93 Cr 17.70 Cr 779.16 Cr 313.70 Cr 6.92 509.00 Cr 0.1441
2023-03-31 1,852.14 Cr 921.36 Cr 930.78 Cr 0.5025 15.89 Cr 16.26 Cr 287.73 Cr 266.31 Cr 6.41 398.63 Cr 0.1438
2022-03-31 1,480.12 Cr 748.02 Cr 732.11 Cr 0.4946 19.25 Cr 24.80 Cr 214.10 Cr 184.57 Cr 4.51 300.73 Cr 0.1247
2021-03-31 1,368.37 Cr 618.60 Cr 749.78 Cr 0.5479 12.87 Cr 23.88 Cr 309.22 Cr 238.54 Cr 5.76 346.30 Cr 0.1743

Annual Financials Balance Sheet

Date C&C Equ. Tot. Assets Tot. Liab. Stock. Equity Tot. Debt Net Debt Inv. PP&E (Net) Curr. Def. Rev. Non-Curr. Def. Rev. LT Invest. Curr. Liab.
2025-03-31 704.21 Cr 3,239.63 Cr 750.25 Cr 2,466.9120 Cr 321.91 Cr -382.30 Cr 845.52 Cr 895.41 Cr 0.00 Cr 0.00 Cr 0.17 Cr 477.3390 Cr
2024-03-31 403.28 Cr 2,680.95 Cr 595.05 Cr 2,065.0540 Cr 244.06 Cr -159.22 Cr 617.94 Cr 693.22 Cr 2.12 Cr 0.00 Cr 0.17 Cr 389.8490 Cr
2023-03-31 382.44 Cr 2,190.39 Cr 425.32 Cr 1,745.1620 Cr 122.95 Cr -259.49 Cr 484.74 Cr 386.89 Cr 41.90 Cr 0.00 Cr -333.24 Cr 340.9900 Cr
2022-03-31 346.26 Cr 1,640.10 Cr 417.13 Cr 1,202.2700 Cr 110.78 Cr -235.48 Cr 424.44 Cr 342.29 Cr 32.50 Cr 0.00 Cr -6.20 Cr 356.2180 Cr
2021-03-31 209.38 Cr 1,228.25 Cr 322.90 Cr 886.4950 Cr 34.10 Cr -175.28 Cr 404.32 Cr 254.02 Cr 41.03 Cr 12.11 Cr 0.84 Cr 298.3994 Cr

Annual Financials Cash Flow Statement

Date Operating Cash Investing Cash Financing Cash Free Cash Cash Change Cash at End CapEx Income Debt Repay Dividends Inventory
2025-03-31 206.6640 Cr -49.0090 Cr -65.1460 Cr 33.7450 Cr 92.5090 Cr 495.7860 Cr -172.9190 Cr 380.5750 Cr -6.0060 Cr -27.1900 Cr -195.4670 Cr
2024-03-31 230.4070 Cr -140.8400 Cr -68.7270 Cr 21.5690 Cr 20.8400 Cr 403.2770 Cr -208.8380 Cr 313.7000 Cr -12.4970 Cr -22.6580 Cr -112.6730 Cr
2023-03-31 237.4120 Cr -259.2120 Cr 197.8290 Cr 183.7810 Cr 176.0310 Cr 382.4370 Cr -53.6310 Cr 337.6530 Cr 5.2960 Cr -10.1710 Cr -44.8500 Cr
2022-03-31 99.2570 Cr -41.6860 Cr 79.5110 Cr 52.9270 Cr 137.0820 Cr 349.2650 Cr -46.3300 Cr 247.5110 Cr 22.5520 Cr -10.5830 Cr -17.8490 Cr
2021-03-31 178.7409 Cr -44.8959 Cr -15.2859 Cr 132.3169 Cr 118.5591 Cr 212.2862 Cr -46.4240 Cr 302.1641 Cr -0.1030 Cr -4.0930 Cr -162.4758 Cr

Quarterly Financial Income Report

Date Revenue Co.Rev GP GPR Operating Income Net Income EPS EBITDA NIR
2025-06-30 619.99 Cr 261.81 Cr 358.18 Cr 0.5777 77.02 Cr 58.32 Cr 1.29 105.76 Cr 0.0941
2025-03-31 708.46 Cr 325.22 Cr 383.24 Cr 0.5409 286.02 Cr 90.55 Cr 2.00 123.86 Cr 0.1278
2024-12-31 681.85 Cr 298.34 Cr 383.50 Cr 0.5624 118.08 Cr 104.56 Cr 2.31 166.61 Cr 0.1534
2024-09-30 641.92 Cr 258.40 Cr 383.53 Cr 0.5975 116.17 Cr 96.72 Cr 2.13 146.74 Cr 0.1507
2024-06-30 590.62 Cr 362.71 Cr 227.91 Cr 0.3859 107.99 Cr 88.75 Cr 1.96 143.39 Cr 0.1503

Quarterly Financials Balance Sheet

Date Cash & Equiv. Short-Term Inv. Cash & Short-Term Net Receivables Inventory Total Curr. Assets PP&E (Net) Total Assets Total Liabilities
2025-03-31 704.21 Cr 208.77 Cr 704.95 Cr 542.19 Cr 845.52 Cr 2,204.12 Cr 895.41 Cr 3,239.63 Cr 750.25 Cr
2024-12-31 0.00 Cr 0.00 Cr 672.03 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr -2,305.12 Cr
2024-09-30 380.97 Cr 15.39 Cr 681.55 Cr 552.48 Cr 758.35 Cr 2,078.51 Cr 686.09 Cr 2,911.32 Cr 606.20 Cr
2024-06-30 0.00 Cr 0.00 Cr 700.57 Cr 0.00 Cr 0.00 Cr 700.57 Cr 0.00 Cr 0.00 Cr -2,085.91 Cr
2024-03-31 673.58 Cr 26.99 Cr 700.57 Cr 453.18 Cr 617.94 Cr 1,862.49 Cr 681.09 Cr 2,680.95 Cr 595.05 Cr

Quarterly Financials Cash Flow Statement

Date Net Income Operating Cash Flow Investing Cash Flow Financing Cash Flow Net Cash Change Cash at End Cash at Beginning CapEx Free Cash Flow
2025-03-31 90.55 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-12-31 104.56 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-09-30 96.72 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-06-30 88.75 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-03-31 78.29 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr

Splits History

Date Label Split Ratio
2008-03-11 March 11, 08 10:1

Similar Stocks: Drug Manufacturers - General

Company Name Symbol Price Market Cap Volume
Cipla Limited CIPLA ₹1,574.60 ₹1,271,889,423,206.00 ₹785,506.00
Abbott India Limited ABBOTINDIA ₹30,980.00 ₹658,303,314,000.00 ₹6,478.00
GlaxoSmithKline Pharmaceuticals Limited GLAXO ₹2,774.00 ₹469,932,244,000.00 ₹120,137.00
Gland Pharma Limited GLAND ₹2,021.20 ₹333,004,827,200.00 ₹242,298.00
Pfizer Limited PFIZER ₹5,227.00 ₹239,123,227,900.00 ₹32,700.00
Sanofi India Limited SANOFI ₹5,067.00 ₹116,693,010,000.00 ₹6,024.00
Marksans Pharma Limited MARKSANS ₹172.93 ₹78,365,650,520.00 ₹665,833.00

Key Executives

Whole-Time Executive Non Independent Director
Ms. Sandra Saldanha

Gender: female

Year Born: 1971

Whole-Time Executive Non Independent Director
Mr. Varddhman Vikramaditya Jain

Gender: male

Year Born: 1970

Managing Director of Australia Operations
Mr. David Mohammed

Gender: male

Year Born:

Non-Independent Executive Chairman & MD
Mr. Mark B. Saldanha

Gender: male

Year Born: 1972

Company Secretary, Manager of Legal & Compliance Officer
Mr. Harshavardhan Panigrahi

Gender: male

Year Born:

Managing Director of UK Operations
Mr. Sathish Kumar

Gender: male

Year Born:

Chief Operating Officer of US Operations
Mr. Anjani Kumar

Gender: male

Year Born: 1960

Director Operations
Mr. Vishal Bhargava

Gender: male

Year Born: 1970

Senior Vice President of QC
Mr. Sunil K. Rane

Gender: male

Year Born: 1969

Chief Financial Officer
Mr. Jitendra M. Sharma

Gender: male

Year Born: 1969

FAQs about Marksans Pharma Limited

Who is the CEO of the company?

The CEO is Mark B. Saldanha.

What is the current market price of the stock?

The current price is ₹172.93.

What is the 52-week price range?

The range is ₹165.52-358.7.

What is the market capitalization of the company?

The market capitalization is ₹7,836.57 crores.

What is the dividend yield?

The dividend yield is 0.81%.

What is the Price-to-Earnings (P/E) ratio?

The P/E ratio is 22.33.

Which sector does the company belong to?

The company operates in the Healthcare sector.

What does the company do?

Overview of Marksans Pharma Limited (ISIN: INE750C01026) is a leading Drug Manufacturers - General in India. With a market capitalization of ₹7,836.57 crores and an average daily volume of 1,488,422 shares, it operates in the Drug Manufacturers - General. The company last declared a dividend of ₹1.4.